CCCC
C4 Therapeutics Inc
$
3.320
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
3.580
Open
3.410
VWAP
3.37
Vol
1.27M
Mkt Cap
317.88M
Low
3.265
Amount
4.28M
EV/EBITDA(TTM)
--
Total Shares
68.81M
EV
-109.29M
EV/OCF(TTM)
--
P/S(TTM)
2.62
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
6.44M
-46.36%
--
--
6.84M
-55.47%
--
--
7.00M
+35.21%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for C4 Therapeutics, Inc. (CCCC) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 130.56%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+130.56%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for C4 Therapeutics Inc (CCCC.O) is -0.97, compared to its 5-year average forward P/E of -6.58. For a more detailed relative valuation and DCF analysis to assess C4 Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-6.58
Current PE
-0.97
Overvalued PE
-0.22
Undervalued PE
-12.93
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-5.34
Current EV/EBITDA
0.39
Overvalued EV/EBITDA
1.71
Undervalued EV/EBITDA
-12.39
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
30.91
Current PS
5.61
Overvalued PS
58.06
Undervalued PS
3.77
Financials
Annual
Quarterly
FY2025Q1
YoY :
+138.17%
7.24M
Total Revenue
FY2025Q1
YoY :
-2.08%
-29.16M
Operating Profit
FY2025Q1
YoY :
-7.19%
-26.32M
Net Income after Tax
FY2025Q1
YoY :
-9.76%
-0.37
EPS - Diluted
FY2025Q1
YoY :
+83.71%
-33.29M
Free Cash Flow
FY2025Q1
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q1
YoY :
-56.38%
-202.36
FCF Margin - %
FY2025Q1
YoY :
-61.03%
-363.66
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
3.6K
USD
2
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
4.3K
Volume
1
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
2
3.4M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
3.6K
USD
2
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CCCC News & Events
Events Timeline
2025-09-04 (ET)
2025-09-04
13:23:42
Brookline optimistic about C4 Therapeutics' prospects following Biogen announcement
2025-09-04
07:12:54
C4 Therapeutics Reveals FDA Acceptance of Biogen's IND for BIIB142
2025-09-03 (ET)
2025-09-03
07:06:51
C4 Therapeutics to Showcase Findings from Phase 1 Study of Cemsidomide
Sign Up For More Events
Sign Up For More Events
News
4.0
09-16NASDAQ.COMStephens & Co. Raises Rating on C4 Therapeutics (CCCC)
4.0
09-15BenzingaStephens & Co. Boosts C4 Therapeutics Rating to Overweight and Increases Price Target to $6
9.0
09-08PRnewswireBreakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market
Sign Up For More News
People Also Watch
PCB
PCB Bancorp
22.110
USD
+3.80%
PAL
Proficient Auto Logistics Inc
7.180
USD
+0.42%
EM
Smart Share Global Ltd
1.360
USD
+0.74%
SATL
Satellogic Inc
3.550
USD
+0.57%
CBAN
Colony Bankcorp Inc
18.260
USD
+4.88%
PLBC
Plumas Bancorp
45.130
USD
+4.15%
VYGR
Voyager Therapeutics Inc
4.485
USD
+5.28%
PCYO
Pure Cycle Corp
11.500
USD
+0.61%
NVX
NOVONIX Ltd
1.320
USD
+3.53%
YMAB
Y-mAbs Therapeutics Inc
0
USD
+0.23%
FAQ
What is C4 Therapeutics Inc (CCCC) stock price today?
The current price of CCCC is 3.32 USD — it has decreased -1.78 % in the last trading day.
What is C4 Therapeutics Inc (CCCC)'s business?
What is the price predicton of CCCC Stock?
What is C4 Therapeutics Inc (CCCC)'s revenue for the last quarter?
What is C4 Therapeutics Inc (CCCC)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for C4 Therapeutics Inc (CCCC)'s fundamentals?
How many employees does C4 Therapeutics Inc (CCCC). have?